The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis； liver fibrosis, including cirrhosis and chronic hepatitis； rheumatoid arthritis； ocular disorders； fibrosis of the skin, including keloid of skin； Dupuytren's Contracture； kidney fibrosis such as nephritis and nephrosclerosis； wound healing； scarring reduction； and a vascular condition, such as restenosis.
